Infinity Pharmaceuticals To Present At B. Riley FBR Institutional Investor Conference

CAMBRIDGE, Mass., May 16, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins, Infinity Pharmaceutical's Chief Executive Officer, will present at the B. Riley FBR Institutional Investor Conference on Thursday, May 23, 2019, at 2:00 p.m. PT (5:00 p.m. ET) at The Beverly Hilton, Beverly Hills, CA. A live webcast of the presentation will be available on the Investors/Media section of Infinity's website at www.infi.com, and will be available for 30 days following the event.

About Infinity
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-1 is an ongoing Phase 1/1b study evaluating IPI-549 as a monotherapy and in combination with Opdivo (nivolumab) in approximately 220 patients with advanced solid tumors including patients refractory to anti-PD-1 therapy. Infinity intends to initiate MARIO-275, a global, randomized, combination study of IPI-549 combined with Opdivo in I/O naïve urothelial cancer patients in 2Q19, as well as to initiate MARIO-3, the first IPI-549 combination study in front-line advanced cancer patients in 2H19. MARIO-3 will evaluate IPI-549 in combination with Tecentriq and Abraxane in front-line TNBC and in combination with Tecentriq and Avastin in front-line RCC. With the addition of MARIO-275 and MARIO-3 to the ongoing MARIO-1 study, Infinity will be evaluating IPI-549 in the anti-PD-1 refractory, I/O-naïve and front-line settings in a total of ~500 patients. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Contact:
Stephanie Ascher, Stern Investor Relations, Inc.
212-362-1200 or [e-mail]

View original content:http://www.prnewswire.com/news-releases/infinity-pharmaceuticals-to-present-at-b-riley-fbr-institutional-investor-conference-300851343.html

SOURCE Infinity Pharmaceuticals, Inc.

Copyright 2019 PR Newswire